Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year

Reports Q4 revenue $30.3M vs. $21.2M last year. “We are rapidly advancing our late-stage pipeline of gene therapies to treat rare and retinal diseases with significant unmet need, with multiple near-term catalysts in 2026,” said Curran Simpson, President and Chief Executive Officer, Regenxbio (RGNX). “We will drive continued momentum across our programs – powered by our fully in-house, end-to-end capabilities, commercial-ready manufacturing, and global partners. We remain focused on executing on our mission to deliver meaningful new medicines to patients in need through the curative potential of gene therapy.” Regenxbio expects its balance in cash, cash equivalents and marketable securities of $240.9M as of December 31, 2025 to fund its operations into early 2027.